The FDA's first quarterly Web posting on potential drug-safety problems, designed to increase transparency with consumers, lacks context and leaves investors and drug sponsors trying to understand its implications, according to this RPM Report analysis. However, the agency's authorities for risk evaluation and mitigation strategies could make the system more predictable and manageable.

Related Summaries